Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Q-Linea, Audiocast with teleconference, Q1'24

By Inderes5/31/2024, 11:00 AM
Q-Linea

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Stuart Gander
00:00 - 26:51

Hello, everyone. Welcome to the call. Happy Friday, and thankIns you for joining this presentation of the Q1 2024 report. You have Stuart Gander here, the CEO speaking. I'm joined by my CFO, Mr. Samuelson, who will speak towards the end of the call. So, we'll split the time between some updates and comments from my side initially. Overall, I'll hand over the baton to Chris, who will speak to our financial update in more detail, and then we'll open up at the end for questions. So with that, I wanted to just start by highlighting a couple of key messages that we would like everyone to take away from the session today. First of all, we're extremely proud and happy to announce that we achieved FDA clearance for our ASTar product as of April 26th, which is a huge breakthrough for us and opens up the US market for full commercial activities. We've been present in the US for some time now with pre-marketing activities. I'll speak to that more in detail in a few minutes. But until we had clearance, we were not able to have full commercial discussions on, for example, pricing, and placing commercial evaluations. So we are now able to do those activities and we're seeing the interest growing in the market commensurately. Secondly, we presented during the quarter some initial results from our ongoing clinical studies with our scientific partners in Europe. These results were presented at a couple of conferences, which I'll speak to in more detail, with a strong reception. And those data coming from the clinical trials are showing very positive results in favor of rapid AST and the potential for improving patient outcomes. Thirdly, we have completed, as of this month, essentially the cost-saving program that we announced earlier. This program is anticipated to generate $50 million of annual savings versus our run rate coming off the back of last cookie.Context year. So, with the completion of the program, we can confirm that we will achieve this target. And those should be fully visible in our financial reports from July onwards. And then finally, from a messages perspective, you will have seen the announcement that we have achieved an additional financial facility from Nexttobe in the form of a loan facility. Chrystia will speak more to the terms of this towards the back end of the call, but this gives us an additional total amount available of $101.5 million, including some of the remaining facility that was available to us before that has been extended. So Chrystia will speak more to those terms, but we're happy to announce that we now have the financial resources to continue our commercialization progress. So with that, I'll go into a few more detailed comments from my view on the quarter and a little bit of year to date. Overall, for me personally, it's been a fast and furious first 90 days in the role as the CEO, having started in March. I did have a month of handover with Eunice Jarvis, which I was very appreciative of, to be able to get up to speed with everything, and I feel that the handover has gone very smoothly. I'm still in regular contact with Jonas and he is still very supportive. Of any questions or needs that we have? From an operational perspective, we're now up and running fully. I've had on my plate four key priorities that I've been pursuing over the past months. Firstly, ensuring that we continue to accelerate our commercial activities and commercial traction in the market. On that note, we did shift our first commercial instrument into Italy. So that is up and running. We announced that tender win earlier and are happy to announce that it has been set up and is now being used clinically. The patients in Bogota are now receiving the benefits of rapid AST, which is very fulfilling for us to see as a team, knowing that we're now having a real clinical impact in the market. As I mentioned, we also had strong reception for our clinical results presented at the Italian conference, where we were able to present to a large audience of attendees. And also at ECCMID, where we shared some posters highlighting the interim findings from those studies. And then finally, on the commercial side, our efforts have really been focused now on ramping up the US pipeline following FDA approval. We have received very strong interest from a number of customers and are now preparing commercial evaluations, which we anticipate will begin in the coming months. And also, in parallel, have continued our efforts across Europe, working with our distributors. We have a number of evaluations on the European side also planned that we expect will materialize into signed contracts and tender wins, hopefully over the coming months. The secondary priority for me has been continuing our innovation in the field of rapid AST and our product development. Obviously, with the keystone here being our FDA approval for our version one menu in the US, we're very pleased. But we don't stop there. We will continue to evolve and expand our offering in rapid AST. So we've already completed a Pre-submission for version two menu into the US that will give us more drug and bug combinations, and we continue our efforts in a focused manner on building out more capabilities inherent to the ASTar platform. Notably, an expansion of the menu into gram-positive bacteria. So our R&D efforts are focused and really oriented around expanding the value proposition from the ASTar platform. My third area of priority over the past months has been around organizational readiness. Obviously coming in, you know, in the process of an organizational restructuring, there was a lot going on. And I wanted to make sure I was spending my time showing that I understood how everything was working at Q-linea and how best to optimize after the restructuring is complete. So with that done, I think we're now in very good shape to pursue our commercial growth agenda and to continue our R&D efforts. The reduction of staff that was implicit in the restructuring program has also enabled us to consolidate the team into a single office. Previously, we were in a couple of locations in the Uppsala Science Park. So this, of course, has some additional benefits of savings on the facility cost side. But I would note that across the team, it's been commented. It's also allowed us to increase the energy and interaction as the team is now all co-located. So, a nice positive from a company culture perspective. And then finally, we have arranged for our third-party logistics in the US in anticipation of the clearance. And now we will be making commercial shipments of our products. So we wanted to ensure that we were set up in advance of that. And we have a good partner in the Raleigh-Durham area who will enable all of our in-market logistics going forward. So that's in place. And then my fourth area of focus has really been around securing and continuing the financial health of the business. Obviously working with Krista and the board and the whole team, working through the cost-saving program to make sure we get everything that was expected from that, and also continuing to look for further ways to optimize our spending, ensuring that we keep the focus on the commercial activities. Overall, I'm very happy to say that we're ahead of the plan. Um, and we're seeing those savings realized in the P&L, even a little bit ahead of plan. For me, the focus going forward is really around achieving top-line growth results. And I'll speak more to what we're doing there. Ensuring that we keep very conscientious use of our resources, aligned with our mission and priority activities. And then I read comments on securing the financial loan from Nexttobe, which gives us now the runway to continue. So with those highlights, I'll go into a few more detailed comments on those points. So, just to expand on the FDA clearance. Those of you who have looked online will have noted. Our panel that's been approved, you can see it here. We're very proud of this. It is the largest panel available for Gram-negative testing in the market, with 18 antibiotics and 12 microbial species. I would highlight that the ASTar platform has a unique capability of providing multiple dilutions for each of the antibiotics, which gives a more granular result for the lab manager and the consulting physician, and therefore a better ability to adjust the treatment for the patient. So, that's a benefit that's just intrinsic to the way the ASTar is designed. This panel, which we are very happy with, allows us to become active in the market right away. We have a larger panel available in Europe, and we will continue to work with the FDA and our clinical work and clinical data work in the background to ensure that we have an approval pathway for an expanded panel. So the value proposition that we're bringing into the market is really centered around. The core features and benefits of the ASTar platform. First of all, a fast turnaround time for clinical results of six hours or less this time versus the standard of care, which can take days. As an immediate benefit, saving lives in sepsis not only helps patients but also saves money for the hospital. It is one of the most overall costly treatments in an in-hospital environment across markets. And also, a quick result means the lab can close the case and reduces the effort and time needed for lab management in following up. And on that note, the actual test platform itself has two minutes or less of hands-on time in the workflow, which is extraordinary in a diagnostic environment. A very simple instrument interface for a lab. Tech requires limited training, very intuitive usage, and it's a true load and go platform, which means there are just a couple of steps to do. You place the cartridge in the disc and the instrument in the lab. Technicians can walk away, and the instrument already indicates exactly when the results will be ready. So they can plan for that in their workflow. And then as I mentioned, you know, this is the most robust menu in the market; it is also the first fully automated random access platform available in the market. With that comprehensive menu, very high reproducibility of results, and the ability to load 12 concurrent patients onto the platform is unique and provides high throughput for the largest labs, even in the US. So I'll speak more to that in a second in terms of our addressable customer base. The results of the US clinical data that were generated were very positive. I won't go into the details here, but you can see the data coming out of our clinical study against the requirements for FDA approval and ISO standards. So the results were extremely robust. We're very proud of that. The chart on the lower right-hand side, which we've shared before, is just an illustration of the total menu potential for the ASTar disc on the gram-negative side versus some selected competitors. And you can see that the benefits of those drug combinations, in combination with the high number of dilution measurements per antibiotic, give us a much more granular result for the physician than anything else available on the market, which we think is a very compelling proposition for labs and physicians. So, what are we focused on now? Our efforts are really tuned to bringing ASTar into the US market. We've obviously started with some of the major players in the space. Prior to FDA approval, we've been engaging with some of the key opinion leaders and research leaders in the field in our early access program, which has meant that a number of facilities and their researchers are now intimately aware of the benefits and the relative superiority of our service over other alternatives. And this will help us in terms of accelerating our commercial efforts in the US market. And what we're really focused on is all the hospitals and labs of medium size and above. This is not a point-of-care solution for a small clinic. But that said, the facilities we're targeting address 90% of the total blood culture sets or the total number of patients for sepsis in the US market. And as I said earlier, our platform is very well tuned to the needs of these extremely busy and physically constrained labs. They have limited amount of bench space, and the ASTar instrument has been elegantly designed to fit well in the lab and have that very easy workflow. So we will be focused on building that pipeline. But we've already got interest from dozens of customers and are now working through the timing essentially for getting those evaluation systems in so customers can try it in real time in their clinic and make the decision for purchasing based on that. So as I mentioned, we were present at ECCMID 2024 in Barcelona. At the end of April. The timing could not have been better since our FDA approval came right at the opening of the conference, which was yet another reason for folks to be interested and come by our booth, which was very busy throughout the conference. I would note that it was very interesting to see that rapid antimicrobial susceptibility testing was one of the overall themes for the conference. There were numerous scientific seminars hosted by researchers in the field, and papers published independent of those that were presented from sponsored investigators. So it is clearly an area of high interest in microbiology. There is an acute awareness of the need for a better solution for sepsis, for the patient population, and a growing awareness of the technical capabilities of these emerging technologies, which we see ASTar as the leading proposition from a technical perspective. So we had a high amount of interest in our booth from customers around the world. This conference is the largest one globally, with almost 16,000 attendees. So it really was interesting to see the level of interest, but also the pre-awareness from customers in Asia, the Middle East, the Americas, etc., who wanted to come by and hear more. This gives us a lot of energy to continue to pursue our global growth ambition and is now translating after the discussions with a number of potential distribution partners, into tangible conversations. We will be expanding our global footprint over the coming months and quarters. And as I mentioned, the clinical evidence base is growing. So both studies that have been sponsored by other third parties and those that we were closely involved with gave us the opportunity to present these to conference attendees in very well attended sessions with a lot of interest. But really, the highlights here are the clinical results that we feel speak for themselves. So we have an ongoing study here. Health economics and outcome research study ongoing in Italy. It's a multi-site study that is generating very robust data, demonstrating that using rapid AST can shorten the time for their patients from between 20 and 34 hours versus the current standard of care in an environment of septic infection. For a patient, that is a tremendous improvement as the ability to adjust therapy and give life-saving drugs in a timely fashion is critical for positive outcomes for patients with sepsis. And what we also see from the full study is that a significant share of those patients, 45% of them, are receiving adjusted therapy. This is in line with previous studies that have indicated that up to half of the patients are receiving suboptimal therapy. And this study is reinforcing that in a real-life environment. And then finally, of those that are receiving adjusted therapy, 46% of them are escalations in the therapy they are receiving. They're getting a more aggressive treatment protocol. So one can infer from that that without the treatment, the drugs that were being used previously would not have been as effective due to the resistance profile of the bacteria and therefore the septic infection outcomes would likely have been much worse. So I think this just speaks to the critical importance of using this, that half the patients are getting their therapy adjusted, and of all the total patients, a quarter of them are being escalated to improved therapy to combat a resistant drug profile. So that for us really speaks to the mission that we're on to improve sepsis outcomes around the world. So, as I've said, on the back of all this, we're really focused on accelerating our commercial efforts. In the near term, it's really about building the pipeline and the markets that we're active in, both through our distribution and direct sales activities in the European market that we've spoken to previously, which we see continuing to generate good feedback. And we anticipate communicating some additional tender wins in the near future. But also, as I keep coming back to, the US market, where we're now fully engaged commercially across the country, is the most important one just due to its sheer size. But also notably, the US is slightly more familiar with rapid AST. We there has been another solution on the market for a longer period of time, which has generated awareness of the technical feasibility and opportunities for rapid AST, and we position ASTar as a next-generation solution with improved technical performance and opportunities for the lab. And therefore we anticipate that adoption will continue to grow in the US. On the back of an improved solution available. As I said, we've got a couple of early access programs ongoing. We've concluded agreements with additional early access candidates and are also now planning for commercial evaluation placements over the coming months. And our efforts don't stop there. We continue with the existing ASTar offering. Obviously, we're very pleased with what's on the market. But we continue to look to the next generation of offerings over the next 12, 24, and 36 months. We're really focused on that expanded panel. So, additional drug combinations, as I mentioned before, will be an evergreen R&D topic for us as the world will benefit from continued innovation in the pharmaceutical side, bringing new drugs to market. That means we need to keep the menu up to date over time. So we will continue to follow the developments in pharmaceutical treatments available for patients and anticipate those. In addition to that, we're continuing our mission to expand the offering into gram-positive and the new ability to use ASTar for isolated testing and additional sample types, such as urine, lung swabs, etc., which we're excited about the opportunity, and we'll develop these over time. I'll speak more in just a second, but we are very proud of the innovations in Hodler and some of the other proof of concept prototypes that we have for Point of Care and our ASTar direct-from-blood solution. These, we see further down the road. So our R&D efforts have been prioritized into ASTar for now. But there's a lot of spillover benefits from the ASTar work that we're doing into other areas. And in order to facilitate. The development of the hardware. We have put that into a separate company structure the which Kristel can speak to in more detail. This has received a third-party valuation of 70 million Swedish crowns, which speaks to the value potential here in Hodler, which really promises to deliver a more efficient management of the blood culture and utilize any time of shipping the blood culture around between the point of drawing the culture where the patient is located and the lab doing the test, using that time already to culture the blood for the test. So, Hodler is a benefit multiplier of the proposition. And setting it up in its own entity here gives us the opportunity to work with additional third parties, both for investment and from a strategic perspective, to bring this into the market. I would say that we are having conversations with customers on Hodler, receiving positive feedback. There's interest here that gives us further motivation to develop the product. So final note there, as I mentioned, concluding the restructuring program, with those benefits fully realized, seen in the P&L from July onward. And looking forward. You know how we're allocating our resources, really concentrating on our commercial activities, especially in the US. At the same time, managing our R&D pipeline, we've reduced the overall investment into our development organization by around half versus our previous run rate coming off last year. But nonetheless able to drive our priority programs in the R&D team. Then obviously we have a bit of our 'keeping the lights on' activities in support of the overall company efforts. But we've also been able to reduce our overheads through the restructuring program considerably, by nearly a quarter. And then the other area that we are attentive to, in terms of the use of our resources, is the deployment of working capital as we scale up our sales activities, both in the form of instruments placed in the field where we expect in Europe, especially, a majority of the instruments we placed under reagent rental contracts, which means we get paid over the duration of the contract, which can typically be between 3 and 5 years. And while in the US, we do expect more capital purchases of instruments that will still be under reagent contracts as well. So this will require some working capital. Christer and the team are already working on alternative options to finance that over time, as we will have signed contracts from customers. So that should enable some alternative ways of financing. But nonetheless, something we need to be planful of in terms of utilizing our precious resources. And then of course, the inventory and the accounts receivable are expected to grow with the business as well. So with that, I think that's a good segue over to Christopher. I'll ask Chris to speak in more detail on our financial results from the quarter, and then we can turn it over for questions. Here sir.

Christopher Samuelson
26:52 - 33:41

Thank you, Stuart. Thank you, Stuart. I'll continue with the financial section and start off with some financial highlights during the first quarter and after the first quarter. As Stuart earlier said, we have a cost-saving program in place. A good start. We have a restructuring cost linked to that of 5 million that will be taken before the half year. It will have been taken in Q2. And then we expect the cost savings to have full effect from Q3 onwards, as you have said before, which is good. We will shift spending from development to more commercial activities. I mean, it's accelerated by the FDA clearance, also outlined by Stuart before. And then we have a decision to transfer the portal technology into a separate company. It's also been valued at 70 million Swedish kronor by an external analysis firm. And the effect on the parent company's financials is primarily that it will strengthen the parent company equity with the same amount and as published before. We have an additional loan facility offered by our main owner Nexttobe. May 29th was Wednesday this week. It's subject to approval by the AGM in June. We had an existing facility of 41.5 million. This additional facility proposed is 60 million. All in all, that means that we have a facility from Nexttobe of 101.5 million Swedish kronor. As of March 31st, we had 29.3 million cash at bank, which means that all in all, including the 60 million that is to be decided on at the upcoming AGM, we have a total of 130.8 million. A little bit on our results. We have an operating result of -18.6 million per month in the first quarter, amounting to -55.9 million for the full quarter. It's better. 6 million better than last year's Q1 in 2023. Continuing and stepping into the consolidated status of the profit and loss for the first quarter. We have top-line revenues. The 2.9 million can be split 50-50 between, sales of instruments and consumables and other operating income, which we are glad to report. As I said before, the operating result was -55.9 million. And it's better than last year. I already said that. And the improvement is primarily linked to the cost-saving program in 2023, which was the first program. The program we have talked about previously; here is the second program for this ver. The company, when reporting the loss of the tax, is -56.5 million, which is better than last year. Earnings per share have experienced a dramatic shift compared to last year. This is, of course, primarily linked to the rights issue last year when the number of shares increased. Quite a lot. You can see that it's 170 million now compared to the 29 million last year. And as I said before, the cost-saving program is already visible but will have its full effect in Q2 and Q3 this year. And the financial position in the first quarter. We repeat some of the numbers here. Cash on hand is 29.3 million. The average monthly decrease from the beginning of the year is 17.5 million. We have a remaining loan facility of 41.5 million as of March. That's a total of 70.8 million as of the end of March. Also, we have a fairly high number of inventories. The amount is 43.5 million. But we are rather happy right now because a large part of that is instruments, which is good as well. Now in this early commercial phase that we are in, which means that we can deliver instruments fairly quickly and be aggressive on that side. The equity as of March is 133.8 million, which is an 18.6 million average monthly decrease during Q1. As you can see here, the equity runway is longer than the liquidity runway. But with the increased loan facility, which was released earlier this week, these two runways will balance. And then stepping into future financing. And still, this will be repeating a bit of what I've said before, just to summarize where we are and how we see it. As I said, we have 70.8 million as of 31st March. After the new or the existing facility for the 15 million has been paid out. 13th of May. And then we have the additional loan facility of 60 million, as I've said before. Which means that we have a total facility of 101.5 million, subject, of the course, to the approval at the AGM. And the third thing I've said before, which we don't need to take again. Uh, and more importantly, in the report, we have reported that we do not have a going concern. Uh, we are in an early commercialization phase. We are FDA cleared, which is very positive. And the pipeline or sales funnel is growing in Europe and in the US. But we have to be engaged in finding other means of financing. And that includes strategic partnerships. Uh, capitalization of existing assets. Stewart mentioned powder, which of course, is one of the assets we might capitalize on. Uh, and then, of course, to negotiate with new and existing investors, financiers, and lenders is always an option. In the light of this, it is the Board of Directors' assessment that the group will successfully be able to finance company operations going forward. That concludes the financial section. Stuart, I hand over to you.

Stuart Gander
33:44 - 33:57

Thank you. Um, and that concludes our presentation portion of the event here. So I'll turn it over to questions. And just.

Operator
33:58 - 34:12

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad.

Stuart Gander
34:14 - 34:17

Uh, Johan, I can see.

Operator
34:17 - 34:22

The next question comes from Johan, a nurse from Redeye. Please go ahead.

Johan
34:25 - 35:00

Hey. Hi there, and thanks for taking our questions. I have a few. Okay. Um, can start off with the pipeline in Europe. You have, uh, instruments commercially, clinically installed already. And you refer to, um, a pipeline of several tenders and also, uh, pilots. Can they what should we expect here over the coming quarters?

Stuart Gander
35:03 - 36:13

Yeah. So the question was related to a European pipeline and sales development. Um, it's always difficult to pinpoint exactly when a tender will close and be announced, you know, down to the month, because it's obviously at the discretion of the customer. But we're, we're active in several tenders right now that we expect to close in the wide-coming months. Uh, obviously can't guarantee that we will win all of them. But we expect to be well placed and are hopeful that these will be positive outcomes for our star. So within the next few months, we would expect to be able to announce some of these. We also, to the extent we can be transparent, will continue to be transparent about the evaluations and the tenders themselves when we enter them. This isn't always an option for us, just given what customers want in terms of what's made public. But we'll keep you all posted as we make the sales and ship the instruments.

Johan
36:16 - 36:34

Good. And to our understanding, the tenders can be of various sizes and perhaps also take different periods of time. Yes, the duration in terms of time can be different as well.

Stuart Gander
36:34 - 37:04

Yes, that's right. We did communicate. One we're very excited about in Italy is the first regional tender of its kind in Tuscany. We communicated that one. It's called the ASTar tender. It's for nine instruments. So that's a significant multicenter placement. We do expect to receive the outcome of that by the end of June. So that should be forthcoming. Hopefully, there will be some others that are in a similar time range as well.

Johan
37:07 - 37:18

Excellent, in terms of the demand, interest, and progress among distributors and on that side.

Stuart Gander
37:20 - 38:36

Yes, so a couple notes there. We did host all of our distributors at our office in Ocala. And we were able to talk through each of the markets in detail. Which was positive to hear, as I said in my comments earlier. Continued growing interest. We do expect to see some evaluation placements in other markets like France and the UK. And the UK actually has some experience already with ASTar. So now we're talking more about the commercial terms with UK customers. But in France, we expect to see some evaluation placements shortly, which should turn into tenders and commercial opportunities down the road as well. So I think the market's now turning; I would characterize France and the UK as being 12 to 18 months behind Italy, which was sort of what we anticipated initially. And, you know, given the timelines of the tender process, we'll have to work through it. But we're now seeing activity that's in line with what we had anticipated. Previously.

Johan
38:38 - 39:00

Excellent. And as you alluded to in the presentation in Europe, it seems like you're expecting more of a rental model. Presumably, that will require less working capital. And in the US eventually, perhaps more of a capital market.

Stuart Gander
39:03 - 39:50

Yes. In the US, in at least my experience, it is more balanced between the two. There will still be customers who want to use the reagent rental model. US health institutions on the whole, and especially the ones that we're focused on initially, tend to be larger and more capitalized organizations that are able to use their balance sheet potential to purchase this type of equipment and correspondingly then want lower operational costs. So, we would sell the instrument upfront and then have a lower price for the consumable than we would in a reagent rental model. I expect to see that more often in the US, even in the near term, than in Europe.

Johan
39:53 - 40:11

And also, congratulations on the FDA approval. You're already in the process then of establishing reimbursement on the N tab. It's impossible to give a flavor of the timelines that we can expect on that side.

Stuart Gander
40:12 - 41:38

Yes, absolutely. And thank you. The FDA approval cannot be understated. And really, I have to pass on that. Congratulations to the team who really carried the ball through that process. I'm enormously proud of what the team has delivered there. With respect to N Tab, having secured FDA approval prior to the May 1st cutoff, came just in time. It is our opinion that we have now achieved all of the criteria needed for NAP. According to the described requirements. That said, CMS will review and make their final determination for N tap funding in October. We're confident that it will be positive, but we will not be able to say for absolute certainty until that October announcement. And the entire funding will not go into effect until January 2025 and will be effective for three years from there. And this is well understood as part of our discussions with customers in the US. So they're anticipating this, and we're able to communicate these timelines to the US and our view that we've qualified. So, it certainly plays into the calculations from customers on their expected end user cost.

Johan
41:39 - 41:45

So it seems like the October feedback from CMS will be important.

Stuart Gander
41:45 - 41:56

Yeah. We'll certainly come back around on that. At this point, I'm confident in a positive outcome. But as I said, I cannot be certain until it's signed and sealed.

Johan
41:58 - 42:19

And you're also rather clear on the nation's need to further improve access to growth capital and financing. And presumably, a positive CMS outcome would also be positive on that side.

Stuart Gander
42:20 - 43:12

Yes, I would expect so. And more generally, I think showing growth in the US market is important, and probably for everyone on this call as well. Right, but being active in the US market also opens us up to a different set of both institutional and investor profiles, something that we are certainly engaged with here. We are staying focused on our mission and delivering results as a team. But I am confident that as we gain traction in the US market, it will change the profile of us as a truly global diagnostic supplier, active and successful in the world's largest and most important diagnostic market. So yes, I think you're on the right line of thinking there.

Johan
43:13 - 43:36

And it seems like you are already engaged in communications with potential US users. Is it possible to provide an update on the level of customer interest at this stage?

Unknown 1
43:36 - 43:37

Yes.

Stuart Gander
43:37 - 46:09

Yes, so I think it's safe to say that we have a couple of dozen active customer dialogues already ongoing. Some of these, as I mentioned, were initiated prior to approval because we were engaging in the early access program environment. But obviously, we were limited in the range of conversation we could have. So it's really only been a month that we've really been able to expand that discussion. But even within that period, I can see from the types of discussions and the number of discussions with the team that the reception is very positive. And I have to be cautious in terms of mentioning the names of specific customers. We will certainly do that as and when it's appropriate and approved by the customers. But I guess I would give assurance to this audience that we are working with major US healthcare institutions. We're in conversation with the largest of the integrated delivery networks, the IDNs, and major reference lab networks in the US. The top ones individually control dozens of labs. So the potential commercial impact from any one of those is very significant. That said, these facilities obviously have a lot of stakeholders. We have a team in the US very well experienced in managing those stakeholders. And they're doing a very diligent and thorough job in engaging with the customers and walking them through. Some of these customers have now been able to see the instrument. The feedback we are receiving is very positive. There is interest in the US, obviously, in what the next version of the menu will look like. Users in the US can see the European menu and you can see it has more combinations than the US one. They understand how this works and it's iterative. The FDA has stringent clinical requirements for approval. Um, and, uh, we're confident we'll be able to get more of, of those in our, in our next iteration of the menu. So we're having that discussion with them. Uh, and, uh, you know, as long as they can see that pipeline of, of, of, uh, further expansion of the menu. I'm confident we'll see them, uh, taking on adoption of, of ASTar in the near future.

Johan
46:11 - 46:48

Excellent. And also regarding the cost base, um, 50 million per year, comprising 50% in R&D and 55% in, uh, some other overheads. Uh, in terms of a reference point, are you okay with this process being completed during Q3? Presumably it has already started. What about Q1 as a starting point? I mean, some of the effects are perhaps visible already. Cuvette. Sorry.

Stuart Gander
46:49 - 46:51

Yeah. Crystal, do you want to speak more to that?

Christopher Samuelson
46:51 - 47:23

I can tell you that one is a good question. You want a starting point, which is always difficult to say, but we have communicated that we have already seen some visibility already in Q1 for the cost saving. Uh, not that much, but still we have some visibility. So, with that said, you cannot take the Q1 average monthly operating result as such. Uh, and then you take the 15 million off that, that doesn't work like that. But it's not too far away.

Johan
47:25 - 47:29

Yeah. So you're in the.

Unknown 1
47:30 - 47:30

First.

Johan
47:30 - 47:31

Quarter of that process, perhaps.

Christopher Samuelson
47:33 - 47:35

Sorry. You want peace again?

Johan
47:36 - 47:42

So perhaps you're in the early stage of that process and maybe in the first quarter or something, if you can try.

Christopher Samuelson
47:43 - 47:48

We are in the early phase, as you said. Yes, but we will see the full effect from Q3 onwards.

Unknown 1
47:49 - 47:50

Yeah.

Stuart Gander
47:51 - 49:12

Yeah. And there are some restructuring costs and so on. So it's not, uh, um, we look at this as the run rate effect. Uh, I would also add on that. You know, our job is never done here, right? We need to keep reshaping the organization. Um, and we're doing that actively. Um, obviously, Kristen and I are looking very closely at the overall financial picture, but working with the entire leadership team at Q-linea to make sure that we're constantly reviewing and evaluating where we're deploying resources and ensuring that it's most efficient and has the best short-to-medium-term return on investment. Uh, so we expect to see continued fine-tuning of the organization as we go forward. Uh, we want to continue to be able to invest into our commercial team and the resources needed to grow our sales, and that will consequently require us to find some space. And in our existing spending, some of that is in terms of headcount in very selective spaces, but also doing everything we can on other discretionary forms of spending, as I mentioned, facilities and things like that. Um, so we'll continue to review our P&L continuously and ensure we're deploying resources appropriately. So I think this will be a moving target throughout the year.

Johan
49:13 - 49:41

Yep. And finally, from our side on Podclub, which is now a separate entity, you had a federation that is supporting equity. Uh, what about the prospects of refinamprehensive financing that separate and perhaps even finding a commercial partner or somebody perhaps even going further than that, but in about 12 months?

Stuart Gander
49:44 - 50:49

Yeah, maybe I can start with that. And you can add on from a financing perspective. So strategically, yes, there is a clear opportunity for a partner. Um, from a commercial perspective, one would benefit, as you suggest, from a partnership with a strategic entity who has the range and the ability to integrate it into existing workflows since it's complementary in a number of ways, also to the existing standard of care. Uh, so, we're continually exploring that opportunity. Um, and also, just from an investment profile, it's at a different stage than ASTar, which is now our focus. So it would benefit from a different type of investor profile to bring that one to market. So, we are having those discussions. Um, I wouldn't want to comment on anything specific at this way. Uh, just given where we're at in those discussions, I know Christopher, if there's anything you want to add in terms of the structuring of that and how we think about it.

Christopher Samuelson
50:50 - 51:06

No, I don't think so. I think I've said before, it's strengthened the parent company equity, which is positive. Other than that, it's, as you said, discussions with separate financing. And then we have shown that toddler has a value which is positive.

Johan
51:08 - 51:09

Great. Thanks.

Stuart Gander
51:10 - 51:11

Thank your John.

Operator
51:16 - 51:24

There are no more phone questions at this time, so I hand the conference back to the speakers for any written questions or closing comments.

Stuart Gander
51:29 - 51:32

So no written questions as I can see it.

Christopher Samuelson
51:33 - 51:34

Me neither.

Stuart Gander
51:35 - 51:43

Okay, so with that, I think we can close the call. Thank you all for your attention. I wish you all a great Friday and a good weekend.

Unknown 1
51:43 - 51:44

Thank you.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…